Sorafenib in Relapsed High Grade Osteosarcoma

Summary

Aim of this exploratory phase II study is to assess the clinical activity of sorafenib as single agent, in terms of percentage of patients with high grade advanced osteosarcoma free from progression following 4 months of therapy

Timeline

Start

2008-01

Primary completion

2010-12

Completion

2011-06

Drugs

Indications